

Jonathan Kimmelman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7954041/jonathan-kimmelman-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

155
papers

4,476
citations

30
h-index

64
g-index

166
ext. papers

5,262
ext. citations

9.5
avg, IF

6.26
L-index

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 155 | How informative were early SARS-CoV-2 treatment and prevention trials? a longitudinal cohort analysis of trials registered on ClinicalTrials.gov.. <i>PLoS ONE</i> , 2022 , 17, e0262114 | 3.7 | 0 |
| 154 | Principal investigators over-optimistically forecast scientific and operational outcomes for clinical trials.. <i>PLoS ONE</i> , 2022 , 17, e0262862 | 3.7 | 2 |
| 153 | Relationship between lay and expert perceptions of COVID-19 vaccine development timelines in Canada and USA.. <i>PLoS ONE</i> , 2022 , 17, e0262740 | 3.7 | |
| 152 | Interventions for physician prescribers of opioids for chronic non-cancer pain: protocol for an overview of systematic reviews.. <i>BMJ Open</i> , 2022 , 12, e060964 | 3 | |
| 151 | Ethical Considerations for Phase I Trials in Oncology.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102125 | 2.2 | 0 |
| 150 | Completeness of clinical evidence citation in trial protocols: A cross-sectional analysis.. <i>Med</i> , 2022 , 3, 335-343.e6 | 31.7 | 1 |
| 149 | Practical steps to identifying the research risk of pragmatic trials.. <i>Clinical Trials</i> , 2022 , 17407745211063476 | 4.6 | |
| 148 | Individualized therapy trials: navigating patient care, research goals and ethics. <i>Nature Medicine</i> , 2021 , 27, 1679-1686 | 50.5 | 2 |
| 147 | Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration. <i>JAMA Network Open</i> , 2021 , 4, e2110456 | 10.4 | 1 |
| 146 | ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update. <i>Stem Cell Reports</i> , 2021 , 16, 1398-1408 | 8 | 27 |
| 145 | The proportion of North American cancer trials that evaluate novel targets. <i>Investigational New Drugs</i> , 2021 , 39, 256-259 | 4.3 | |
| 144 | Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 171-177 | 7 | 1 |
| 143 | Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases. <i>Annals of Internal Medicine</i> , 2021 , 174, 326-334 | 8 | 7 |
| 142 | Commentary on Kahrass et al: The sublime inertia of informed consent language in early phase clinical trials involving patients. <i>Clinical Trials</i> , 2021 , 18, 81-82 | 2.2 | 1 |
| 141 | Systematic review and narrative review lead experts to different cancer trial predictions: a randomized trial. <i>Journal of Clinical Epidemiology</i> , 2021 , 132, 116-124 | 5.7 | 2 |
| 140 | Can Oncologists Predict the Efficacy of Treatments in Randomized Trials?. <i>Oncologist</i> , 2021 , 26, 56-62 | 5.7 | 4 |
| 139 | Let's do better: public representations of COVID-19 science. <i>Facets</i> , 2021 , 6, 403-423 | 2.3 | 7 |

| | | | |
|-----|--|------|----|
| 138 | The Effect of Overdose Education and Naloxone Distribution: An Umbrella Review of Systematic Reviews. <i>American Journal of Public Health</i> , 2021 , 111, e1-e12 | 5.1 | 4 |
| 137 | Is preclinical research in cancer biology reproducible enough?. <i>ELife</i> , 2021 , 10, | 8.9 | 1 |
| 136 | The Efficacy and Safety of Low Molecular Weight Heparin Administration to Improve Survival of Cancer Patients: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 832-846 | 7 | 8 |
| 135 | Forecasts for the Attainment of Major Research Milestones in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 1047-1055 | 5.3 | 3 |
| 134 | Wisdom of the expert crowd prediction of response for 3 neurology randomized trials. <i>Neurology</i> , 2020 , 95, e488-e498 | 6.5 | 1 |
| 133 | A systematic review and meta-analysis of pregabalin preclinical studies. <i>Pain</i> , 2020 , 161, 684-693 | 8 | 10 |
| 132 | Clinical development success rates and social value of pediatric Phase 1 trials in oncology. <i>PLoS ONE</i> , 2020 , 15, e0234911 | 3.7 | 2 |
| 131 | Decision analysis approach to risk/benefit evaluation in the ethical review of controlled human infection studies. <i>Bioethics</i> , 2020 , 34, 764-770 | 2 | |
| 130 | What Research Ethics (Often) Gets Wrong about Minimal Risk. <i>American Journal of Bioethics</i> , 2020 , 20, 42-44 | 1.1 | 3 |
| 129 | Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 886-892 | 9.7 | 8 |
| 128 | Clinical Trials, Ethics, and Human Protections Policies 2020 , 1-18 | | |
| 127 | Identifying and understanding factors that affect the translation of therapies from the laboratory to patients: a study protocol. <i>F1000Research</i> , 2020 , 9, 485 | 3.6 | 2 |
| 126 | Impact of Precision Medicine on Efficiencies of Novel Drug Development in Cancer. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 859-862 | 9.7 | 2 |
| 125 | Reply to 'Correcting the ASCO position on phase I clinical trials in cancer'. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 125-126 | 19.4 | 1 |
| 124 | Group sample sizes in nonregulated health care intervention trials described as randomized controlled trials were overly similar. <i>Journal of Clinical Epidemiology</i> , 2020 , 120, 8-16 | 5.7 | |
| 123 | Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease. <i>Neurology</i> , 2020 , 94, e1-e14 | 6.5 | 16 |
| 122 | Imatinib and the long tail of targeted drug development. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 1-3 | 19.4 | 13 |
| 121 | Ethical and Policy Issues for Seamless Phase I Oncology Trials. <i>Journal of Clinical Oncology</i> , 2020 , 38, 669-673 | 6.7 | 9 |

| | | | |
|-----|---|------|-----|
| 120 | Response to Moisset et al. <i>Pain</i> , 2020 , 161, 2427-2428 | 8 | |
| 119 | Why IRBs should protect bystanders in human research. <i>Bioethics</i> , 2020 , 34, 933-936 | 2 | 1 |
| 118 | Expert Forecasts of COVID-19 Vaccine Development Timelines. <i>Journal of General Internal Medicine</i> , 2020 , 35, 3753-3755 | 4 | 8 |
| 117 | What Is Human Research For? Reflections on the Omission of Scientific Integrity from the. <i>Perspectives in Biology and Medicine</i> , 2020 , 63, 251-261 | 1.5 | 3 |
| 116 | Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study. <i>BMJ Open</i> , 2020 , 10, e034306 | 3 | 2 |
| 115 | Benefit, burden, and impact for a cohort of post-approval cancer combination trials. <i>Clinical Trials</i> , 2020 , 17, 18-29 | 2.2 | 3 |
| 114 | Comparison between protocols and publications for prognostic and predictive cancer biomarker studies. <i>Clinical Trials</i> , 2020 , 17, 61-68 | 2.2 | 5 |
| 113 | Against pandemic research exceptionalism. <i>Science</i> , 2020 , 368, 476-477 | 33.3 | 171 |
| 112 | Clinical development success rates and social value of pediatric Phase 1 trials in oncology 2020 , 15, e0234911 | | |
| 111 | Clinical development success rates and social value of pediatric Phase 1 trials in oncology 2020 , 15, e0234911 | | |
| 110 | Clinical development success rates and social value of pediatric Phase 1 trials in oncology 2020 , 15, e0234911 | | |
| 109 | Clinical development success rates and social value of pediatric Phase 1 trials in oncology 2020 , 15, e0234911 | | |
| 108 | Clinical development success rates and social value of pediatric Phase 1 trials in oncology 2020 , 15, e0234911 | | |
| 107 | Clinical development success rates and social value of pediatric Phase 1 trials in oncology 2020 , 15, e0234911 | | |
| 106 | Phase I trials as therapeutic options: (usually) a betrayal of evidence-based medicine. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 719-720 | 19.4 | 8 |
| 105 | How well are Phase 2 cancer trial publications supported by preclinical efficacy evidence?. <i>International Journal of Cancer</i> , 2019 , 145, 3370-3375 | 7.5 | 2 |
| 104 | Ethical Review and Methodologic Innovation in Phase 1 Cancer Trials-Reply. <i>JAMA Pediatrics</i> , 2019 , 173, 609-610 | 8.3 | |
| 103 | The PLOS Biology XV Collection: 15 Years of Exceptional Science Highlighted across 12 Months. <i>PLoS Biology</i> , 2019 , 17, e3000180 | 9.7 | 1 |

| | | | |
|-----|---|------|----|
| 102 | Evaluation of Journal Registration Policies and Prospective Registration of Randomized Clinical Trials of Nonregulated Health Care Interventions. <i>JAMA Internal Medicine</i> , 2019 , 179, 624-632 | 11.5 | 16 |
| 101 | Potential harms from legalization of recreational cannabis use in Canada. <i>Canadian Journal of Public Health</i> , 2019 , 110, 222-226 | 3.2 | 21 |
| 100 | Clinical Trial Portfolios: A Critical Oversight in Human Research Ethics, Drug Regulation, and Policy. <i>Hastings Center Report</i> , 2019 , 49, 31-41 | 3.3 | 12 |
| 99 | Organ donor intervention trials and the ethical challenge of bystander organ recipients. <i>Clinical Trials</i> , 2019 , 16, 461-462 | 2.2 | 0 |
| 98 | Regulating impact on bystanders in clinical trials: An unsettled frontier. <i>Clinical Trials</i> , 2019 , 16, 450-454 | 2.2 | 4 |
| 97 | Harms From Uninformative Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 813-814 | 27.4 | 36 |
| 96 | Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies. <i>Molecular Therapy - Oncolytics</i> , 2019 , 14, 179-187 | 6.4 | 11 |
| 95 | Ethical development of stem-cell-based interventions. <i>Nature Medicine</i> , 2019 , 25, 1037-1044 | 50.5 | 17 |
| 94 | Participant Protection in Phase 1 Pediatric Cancer Trials. <i>JAMA Pediatrics</i> , 2019 , 173, 8-9 | 8.3 | 6 |
| 93 | Assessment of Pregabalin Postapproval Trials and the Suggestion of Efficacy for New Indications: A Systematic Review. <i>JAMA Internal Medicine</i> , 2019 , 179, 90-97 | 11.5 | 16 |
| 92 | The paradox of precision medicine. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 341-342 | 19.4 | 23 |
| 91 | Clinical Trials in Medical Center Advertising. <i>JAMA Oncology</i> , 2018 , 4, 769-770 | 13.4 | 5 |
| 90 | Preclinical efficacy studies in investigator brochures: Do they enable risk-benefit assessment?. <i>PLoS Biology</i> , 2018 , 16, e2004879 | 9.7 | 39 |
| 89 | Trials that say "maybe": the disconnect between exploratory and confirmatory testing after drug approval. <i>BMJ, The</i> , 2018 , 360, k959 | 5.9 | 11 |
| 88 | Better to be in The Placebo Arm for Trials of Neurological Therapies?. <i>Cell Transplantation</i> , 2018 , 27, 677-681 | 4 | 5 |
| 87 | Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis. <i>PLoS Medicine</i> , 2018 , 15, e1002505 | 11.6 | 20 |
| 86 | The stem cell market and policy options: a call for clarity. <i>Journal of Law and the Biosciences</i> , 2018 , 5, 743-758 | 4.1 | 8 |
| 85 | The bench is closer to the bedside than we think: Uncovering the ethical ties between preclinical researchers in translational neuroscience and patients in clinical trials. <i>PLoS Biology</i> , 2018 , 16, e2006343 | 9.7 | 15 |

| | | | |
|----|--|------|----|
| 84 | Preclinical efficacy in therapeutic area guidelines from the U.S. Food and Drug Administration and the European Medicines Agency: a cross-sectional study. <i>British Journal of Pharmacology</i> , 2018 , 175, 4229-4238 ¹¹ | 8.6 | 11 |
| 83 | Ethical issues in the development of oncology drugs. <i>Clinical Advances in Hematology and Oncology</i> , 2018 , 16, 644-647 | 0.6 | |
| 82 | The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing. <i>Oncologist</i> , 2017 , 22, 89-96 | 5.7 | 5 |
| 81 | Nonpublication of trial results for new neurological drugs: A systematic review. <i>Annals of Neurology</i> , 2017 , 81, 782-789 | 9.4 | 6 |
| 80 | Increasing efficiency of preclinical research by group sequential designs. <i>PLoS Biology</i> , 2017 , 15, e2001307 | 9.7 | 25 |
| 79 | Drug Development at the Portfolio Level Is Important for Policy, Care Decisions and Human Protections. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 1003-1004 | 27.4 | 5 |
| 78 | Burdensome Research Procedures in Trials: Why Less Is More. <i>Journal of the National Cancer Institute</i> , 2017 , 109, | 9.7 | 14 |
| 77 | Is Participation in Cancer Phase I Trials Really Therapeutic?. <i>Journal of Clinical Oncology</i> , 2017 , 35, 135-138 | 2 | 35 |
| 76 | Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. <i>PLoS Biology</i> , 2017 , 15, e2000487 | 9.7 | 26 |
| 75 | Can cancer researchers accurately judge whether preclinical reports will reproduce?. <i>PLoS Biology</i> , 2017 , 15, e2002212 | 9.7 | 14 |
| 74 | Consider drug efficacy before first-in-human trials. <i>Nature</i> , 2017 , 542, 25-27 | 50.4 | 38 |
| 73 | Design and Reporting of Targeted Anticancer Preclinical Studies: A Meta-Analysis of Animal Studies Investigating Sorafenib Antitumor Efficacy. <i>Cancer Research</i> , 2016 , 76, 4627-36 | 10.1 | 12 |
| 72 | Accelerated Drug Approval and Health Inequality. <i>JAMA Internal Medicine</i> , 2016 , 176, 883-4 | 11.5 | 6 |
| 71 | How do researchers decide early clinical trials?. <i>Medicine, Health Care and Philosophy</i> , 2016 , 19, 191-8 | 2 | 3 |
| 70 | Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib. <i>Journal of the National Cancer Institute</i> , 2016 , 108, | 9.7 | 32 |
| 69 | Assessing risk/benefit for trials using preclinical evidence: a proposal. <i>Journal of Medical Ethics</i> , 2016 , 42, 50-3 | 2.5 | 25 |
| 68 | Policy: Global standards for stem-cell research. <i>Nature</i> , 2016 , 533, 311-3 | 50.4 | 33 |
| 67 | Ensemble Space and the Ethics of Clinical Development. <i>Research Ethics Forum</i> , 2016 , 137-151 | 0.2 | |

| | | | |
|----|---|------|-----|
| 66 | Where Have All the Rodents Gone? The Effects of Attrition in Experimental Research on Cancer and Stroke. <i>PLoS Biology</i> , 2016 , 14, e1002331 | 9.7 | 55 |
| 65 | The Research Optimist's Defense. <i>Perspectives in Biology and Medicine</i> , 2016 , 59, 491-506 | 1.5 | |
| 64 | Do We Know Whether Researchers and Reviewers are Estimating Risk and Benefit Accurately?. <i>Bioethics</i> , 2016 , 30, 609-17 | 2 | 9 |
| 63 | Ethical considerations of e-cigarette use for tobacco harm reduction. <i>Respiratory Research</i> , 2016 , 17, 53 | 7.3 | 24 |
| 62 | SCIENTIFIC COMMUNITY. Confronting stem cell hype. <i>Science</i> , 2016 , 352, 776-7 | 33.3 | 86 |
| 61 | New ISSCR guidelines: clinical translation of stem cell research. <i>Lancet, The</i> , 2016 , 387, 1979-81 | 4.0 | 33 |
| 60 | Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines. <i>Stem Cell Reports</i> , 2016 , 6, 787-797 | 8 | 136 |
| 59 | Patient-Funded Trials: Opportunity or Liability?. <i>Cell Stem Cell</i> , 2015 , 17, 135-7 | 18 | 19 |
| 58 | Are outcome-adaptive allocation trials ethical?. <i>Clinical Trials</i> , 2015 , 12, 102-6 | 2.2 | 77 |
| 57 | Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials. <i>Clinical Trials</i> , 2015 , 12, 77-83 | 2.2 | 158 |
| 56 | Elements of informed consent and decision quality were poorly correlated in informed consent documents. <i>Journal of Clinical Epidemiology</i> , 2015 , 68, 1472-80 | 5.7 | 15 |
| 55 | Rejoinder. <i>Clinical Trials</i> , 2015 , 12, 125-7 | 2.2 | 7 |
| 54 | The structure of clinical translation: efficiency, information, and ethics. <i>Hastings Center Report</i> , 2015 , 45, 27-39 | 3.3 | 34 |
| 53 | Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials. <i>BMJ, The</i> , 2015 , 350, h1116 | 5.9 | 21 |
| 52 | A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib. <i>ELife</i> , 2015 , 4, e08351 | 8.9 | 27 |
| 51 | Why clinical translation cannot succeed without failure. <i>ELife</i> , 2015 , 4, e12844 | 8.9 | 15 |
| 50 | Ethics of Cancer Gene Transfer Clinical Research. <i>Methods in Molecular Biology</i> , 2015 , 1317, 263-85 | 1.4 | 2 |
| 49 | Clinical Translation in Central Nervous System Diseases: Ethical and Social Challenges 2015 , 1107-1124 | | |

| | | | |
|----|--|------|-----|
| 48 | The risk-escalation model: a principled design strategy for early-phase trials. <i>Kennedy Institute of Ethics Journal</i> , 2014 , 24, 121-39 | 1.1 | 17 |
| 47 | Distinguishing between exploratory and confirmatory preclinical research will improve translation. <i>PLoS Biology</i> , 2014 , 12, e1001863 | 9.7 | 136 |
| 46 | The questionable use of unequal allocation in confirmatory trials. <i>Neurology</i> , 2014 , 82, 77-9 | 6.5 | 61 |
| 45 | Are phase 1 trials therapeutic? Risk, ethics, and division of labor. <i>Bioethics</i> , 2014 , 28, 138-46 | 2 | 9 |
| 44 | Consent for nondiagnostic research biopsies: a pilot study of participant recall and therapeutic orientation. <i>IRB: Ethics & Human Research</i> , 2014 , 36, 9-15 | | 8 |
| 43 | Position statement on the provision and procurement of human eggs for stem cell research. <i>Cell Stem Cell</i> , 2013 , 12, 285-91 | 18 | 6 |
| 42 | Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments. <i>PLoS Medicine</i> , 2013 , 10, e1001489 | 11.6 | 182 |
| 41 | Ethics, error, and initial trials of efficacy. <i>Science Translational Medicine</i> , 2013 , 5, 184fs16 | 17.5 | 6 |
| 40 | Ethics, ambiguity aversion, and the review of complex translational clinical trials. <i>Bioethics</i> , 2012 , 26, 242-50 | 2 | 13 |
| 39 | Beyond human subjects: risk, ethics, and clinical development of nanomedicines. <i>Journal of Law, Medicine and Ethics</i> , 2012 , 40, 841-7 | 1.2 | 7 |
| 38 | A theoretical framework for early human studies: uncertainty, intervention ensembles, and boundaries. <i>Trials</i> , 2012 , 13, 173 | 2.8 | 32 |
| 37 | Should preclinical studies be registered?. <i>Nature Biotechnology</i> , 2012 , 30, 488-9 | 44.5 | 57 |
| 36 | Research ethics. Rethinking research ethics: the case of postmarketing trials. <i>Science</i> , 2012 , 336, 544-5 | 33.3 | 26 |
| 35 | Publication and reporting conduct for pharmacodynamic analyses of tumor tissue in early-phase oncology trials. <i>Clinical Cancer Research</i> , 2012 , 18, 6478-84 | 12.9 | 21 |
| 34 | The social function of clinical equipoise. <i>Clinical Trials</i> , 2012 , 9, 630-1 | 2.2 | 7 |
| 33 | Analysis of consent validity for invasive, nondiagnostic research procedures. <i>IRB: Ethics & Human Research</i> , 2012 , 34, 1-7 | | 95 |
| 32 | Risk of surgical delivery to deep nuclei: a meta-analysis. <i>Movement Disorders</i> , 2011 , 26, 1415-21 | 7 | 43 |
| 31 | Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty. <i>PLoS Medicine</i> , 2011 , 8, e1001010 | 11.6 | 65 |

| | | | |
|----|--|------|----|
| 30 | Ethics and Uncertainty: Considerations for the Design and Review of Translational Trials Involving Stem Cells. <i>Pancreatic Islet Biology</i> , 2011 , 403-418 | 0.4 | 2 |
| 29 | Extending clinical equipoise to phase 1 trials involving patients: unresolved problems. <i>Kennedy Institute of Ethics Journal</i> , 2010 , 20, 75-98 | 1.1 | 29 |
| 28 | Research ethics. Beyond access vs. protection in trials of innovative therapies. <i>Science</i> , 2010 , 328, 829-303 | 3.3 | 54 |
| 27 | Tomorrow, interrupted? Risk, ethics, and medical advance in gene transfer. <i>Molecular Therapy</i> , 2009 , 17, 1838-9 | 11.7 | 6 |
| 26 | Launching invasive, first-in-human trials against Parkinson's disease: ethical considerations. <i>Movement Disorders</i> , 2009 , 24, 1893-901 | 7 | 28 |
| 25 | Battling a thousand points of might. <i>Hastings Center Report</i> , 2009 , 39, 3 | 3.3 | |
| 24 | Helsinki discords: FDA, ethics, and international drug trials. <i>Lancet, The</i> , 2009 , 373, 13-4 | 4.0 | 43 |
| 23 | Ethics of cancer gene transfer clinical research. <i>Methods in Molecular Biology</i> , 2009 , 542, 423-45 | 1.4 | 7 |
| 22 | Gene Transfer and the Ethics of First-in-Human Research: Lost in Translation 2009 , | | 36 |
| 21 | CLINICAL TRIALS AND SCID ROW: THE ETHICS OF PHASE 1 TRIALS IN THE DEVELOPING WORLD. <i>Developing World Bioethics</i> , 2007 , 7, 128-135 | 2.6 | 7 |
| 20 | The therapeutic misconception at 25: treatment, research, and confusion. <i>Hastings Center Report</i> , 2007 , 37, 36-42 | 3.3 | 77 |
| 19 | Inventors as investigators: the ethics of patents in clinical trials. <i>Academic Medicine</i> , 2007 , 82, 24-31 | 3.9 | 6 |
| 18 | Stable ethics: enrolling non-treatment-refractory volunteers in novel gene transfer trials. <i>Molecular Therapy</i> , 2007 , 15, 1904-6 | 11.7 | 14 |
| 17 | Missing the forest: further thoughts on the ethics of bystander risk in medical research. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2007 , 16, 483-90 | 0.9 | 13 |
| 16 | Faithful companions: a proposal for neurooncology trials in pet dogs. <i>Cancer Research</i> , 2007 , 67, 4541-4 | 10.1 | 37 |
| 15 | Towards a global human embryonic stem cell bank: differential termination. <i>American Journal of Bioethics</i> , 2007 , 7, 52-3; discussion W4-6 | 1.1 | 2 |
| 14 | Clinical trials and SCID row: the ethics of phase 1 trials in the developing world. <i>Developing World Bioethics</i> , 2007 , 7, 128-35 | 2.6 | 3 |
| 13 | Recent developments in gene transfer: risk and ethics. <i>BMJ, The</i> , 2005 , 330, 79-82 | 5.9 | 60 |

| | | | |
|----|---|------|------|
| 12 | Medical Research, Risk, and Bystanders. <i>IRB: Ethics & Human Research</i> , 2005 , 27, 1 | | 21 |
| 11 | Elements of style: consent form language and the therapeutic misconception in phase 1 gene transfer trials. <i>Human Gene Therapy</i> , 2005 , 16, 502-8 | 4.8 | 15 |
| 10 | Medical research, risk, and bystanders. <i>IRB: Ethics & Human Research</i> , 2005 , 27, 1-6 | | 9 |
| 9 | Valuing risk: the ethical review of clinical trial safety. <i>Kennedy Institute of Ethics Journal</i> , 2004 , 14, 369-93 | 1.1 | 24 |
| 8 | Protection at the cutting edge: the case for central review of human gene transfer research. <i>Cmaj</i> , 2003 , 169, 781-2 | 3.5 | 2 |
| 7 | Sunburn and p53 in the onset of skin cancer. <i>Nature</i> , 1994 , 372, 773-6 | 50.4 | 1520 |
| 6 | Introduction: gene transfer lost in translation1-7 | | |
| 5 | The chasm: the ethics of initiating first-in-human clinical trials110-131 | | |
| 4 | Tropic of cancers: gene transfer in resource-poor settings132-152 | | |
| 3 | Something in the sight adjusts itself: conclusions178-191 | | |
| 2 | Identifying and understanding factors that affect the translation of therapies from the laboratory to patients: a study protocol. <i>F1000Research</i> , 9 , 485 | 3.6 | 1 |
| 1 | Patient Benefit and Risk in Anticancer Drug Development: A Systematic Review of the Ixabepilone Trial Portfolio | | 1 |